Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 2
1(20.0%)
5Total
N/A(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04598295Phase 2Completed

SH-DS01 on Fecal Metagenomic Stability

Role: collaborator

NCT06236893Not ApplicableCompleted

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

Role: lead

NCT05659745Not ApplicableCompleted

Randomized, Double-blind, Placebo-controlled Trial Investigating the Role of a Personal Care Product on Vaginal Health

Role: lead

NCT04534036Not ApplicableCompleted

Tolerability and Functional Assessment of a Novel Children's Synbiotic

Role: lead

NCT04171466Not ApplicableCompleted

Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy

Role: lead

All 5 trials loaded